Advanced search
Publication Cover
COPD: Journal of Chronic Obstructive Pulmonary Disease Volume 13, 2016 - Issue 5
Submit an article Journal homepage
539
Views
10
CrossRef citations to date
0
Altmetric
Original Research

Incidence, Predictors, and Clinical Implications of Discontinuing Therapy with Inhaled Long-Acting Bronchodilators among Patients with Chronic Obstructive Pulmonary Disease

Andrea ArfèLaboratory of Healthcare Research and Pharmacoepidemiology, Unit of Biostatistics, Epidemiology, and Public Health, Department of Statistics and Quantitative Methods, University of Milano-Bicocca, Milan, Italy
,
Federica NicotraLaboratory of Healthcare Research and Pharmacoepidemiology, Unit of Biostatistics, Epidemiology, and Public Health, Department of Statistics and Quantitative Methods, University of Milano-Bicocca, Milan, Italy
,
Isa CerveriInstitute of Respiratory Diseases, University of Sassari, Sassari, Italy
,
Roberto de MarcoUnit of Epidemiology and Medical Statistics, University of Verona, Verona, Italy
,
Adriano VaghiDivision of Pneumology, “Guido Salvini” Hospital, Garbagnate Milanese, Italy
,
Luca MerlinoOperative Unit of Territorial Health Services, Region Lombardia, Milan, Italy
&
Giovanni CorraoLaboratory of Healthcare Research and Pharmacoepidemiology, Unit of Biostatistics, Epidemiology, and Public Health, Department of Statistics and Quantitative Methods, University of Milano-Bicocca, Milan, ItalyCorrespondence[email protected]
 show all
Pages 540-546 | Received 02 Jul 2015, Accepted 22 Dec 2015, Published online: 02 Mar 2016

References

  • Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest 2000; 117(2 Suppl):5S–9S.
  • Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007; 370(9589):765–73.
  • Breekveldt-Postma NS, Koerselman J, Erkens JA, Lammers JWJ, Herings RMC. Enhanced persistence with tiotropium compared with other respiratory drugs in COPD. Respir Med 2007; 101(7):1398–405.
  • Toy EL, Beaulieu NU, McHale JM, Welland TR, Plauschinat CA, Swensen A, et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med 2011; 105(3):435–41.
  • Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2015. Available from: http://www.goldcopd.org/ (Accessed August 25, 2015).
  • Vestbo J, Anderson JA, Calverley PM, Celli B, Ferguson GT, Jenkins C, et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax 2009; 64(11):939–43.
  • Kesten S, Flanders J, Serby CW, Witek TJ. Compliance with tiotropium, a once daily dry powder inhaled bronchodilator, in one year COPD trials. Chest 2000; 118(4):191S–2S.
  • Rand CS, Nides M, Cowles MK, Wise RA, Connett J. Long-term metered-dose inhaler adherence in a clinical trial. The Lung Health Study Research Group. Am J Respir Critical Care Med 1995; 152(2):580–8.
  • Bender BG, Pedan A, Varasteh LT. Adherence and persistence with fluticasone propionate/salmeterol combination therapy. J Allergy Clin Immunol 2006; 118(4):899–904.
  • Breekveldt-Postma NS, Gerrits CM, Lammers JW, Raaijmakers JA, Herings RM. Persistence with inhaled corticosteroid therapy in daily practice. Respir Med 2004; 98(8):752–9.
  • Krigsman K, Nilsson JL, Ring L. Refill adherence for patients with asthma and COPD: comparison of a pharmacy record database with manually collected repeat prescriptions. Pharmacoepidemiol Drug Saf 2007; 16(4):441–8.
  • Antoniu SA. Adherence to inhaled therapy in COPD: effects on survival and exacerbations. Expert Rev Pharmacoecon Outcomes Res 2010; 10(2):115–7.
  • Mäkelä MJ, Backer V, Hedegaard M, Larsson K. Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. Respir Med 2013; 107(10):1481–90.
  • Covvey JR, Mullen AB, Ryan M, Steinke DT, Johnston BF, Wood FT, et al. A Comparison of medication adherence/persistence for asthma and chronic obstructive pulmonary disease in the United Kingdom. Int J Clin Pract 2014; 68(10):1200–8.
  • Corrao G, Mancia G. Generating evidence from computerized healthcare utilization databases. Hypertension 2015; 65(3):490–8.
  • Charlson ME, Charlson RE, Peterson JC, Marinopoulos SS, Briggs WM, Hollenberg JP. The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol 2008; 61(12):1234–40.
  • Marubini E, Valsecchi MG. Analysing survival data from clinical trials and observational studies. New York: John Wiley & Sons; 1995.
  • Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol 1991; 133(2):144–53.
  • Wang S, Linkletter C, Maclure M, Dore D, Mor V, Buka S, et al. Future cases as present controls to adjust for exposure trend bias in case-only studies. Epidemiology 2011; 22(4):568–74.
  • Cramer JA, Bradley-Kennedy C, Scalera A. Treatment persistence and compliance with medications for chronic obstructive pulmonary disease. Can Respir J 2007; 14(1):25–9.
  • Balkrishnan R, Christensen DB. Inhaled corticosteroid use and associated outcomes in elderly patients with moderate to severe pulmonary disease. Clin Ther 2000; 22(4):452–69.
  • Rand CS, Nides M, Cowles MK, Wise RA, Connett J. Long-term metered-dose inhaler adherence in a clinical trial. The Lung Health Study Research Group. Am J Respir Crit Care Med 1995; 152(2):580–8.
  • Elkout H, Helms PJ, Simpson CR, McLay JS. Adequate levels of adherence with controller medication is associated with increased use of rescue medication in asthmatic children. PLoS ONE 2012; 7:e39130.
  • World Health Organization (WHO). Adherence to long-term therapies: evidence for action, 2003. Available from: http://www.who.int/chp/knowledge/publications/adherence_full_report.pdf (Accessed July 18, 2015).
  • Roede BM, Bindels PJE, Brouwer HJ, Bresser P, de Borgie CAJM, Prins JM. Antibiotics and steroids for exacerbations of COPD in primary care: compliance with Dutch guidelines. Br J Gen Pract 2006; 56(530):662–5.
  • Maclure M, Mittleman MA. Should we use a case-crossover design? Annu Rev Public Health 2000; 21:193–221.
  • Wang SV, Gagne JJ, Glynn RJ, Schneeweiss S. Case-crossover studies of therapeutics: design approaches to addressing time-varying prognosis in elderly populations. Epidemiology 2013; 24(3):375–8.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.